DDIT3 and diffuse large B-cell lymphoma: This was specifically demonstrated for systemic DLBCL in Wright et al where excellent response of the MCD and N1 subgroups to BTKi was demonstrated.9 Systemic DLBCL of the subtypes MCD and N1 have a robust response to BTKi,16 with 100% 5-year event free survival (PFS) in younger patients when treated with BTKi plus R-CHOP versus <50% with R-CHOP alone).